The highest reward for reporting violations of laws and regulations of pharmaceutical enterprises is 200W. It is difficult for the State Council to issue measures to collect funds from the hospital

The highest reward is 200W for reporting violations of laws and regulations of pharmaceutical enterprises; Is it difficult for hospitals to collect money? The State Council gives solutions; The R & D cost of listed companies is amazing, and R & d really costs money; Great writing! 5 billion yuan for modern Chinese medicine; On November 19, the State Food and Drug Administration issued the revision requirements for the manual of brain glycoside and carnosine injection and the revision requirements for the manual of compound bone peptide injection This kind of injection belongs to the national key monitoring drugs, and has been included in the list of key monitoring drugs in many places Warning words are added to the drug Manual of brain glycoside and carnosine injection This product contains monosialotetrahexosylganglioside and related warnings that may produce Guillain Barre syndrome On the basis of the original instructions, compound osteopeptide injection is forbidden in children, pregnant women and lactating women, and those with severe liver and kidney dysfunction Brief comment: in this way, it may completely block the opportunity for drug companies to drill holes and further strengthen the key monitoring of drugs It can be said that there is not much time left for the transformation of relevant enterprises Once the list of key monitoring drugs is spread across the country, the situation will only be more serious than now On November 12, the executive meeting of the State Council called for promoting the reform of medical insurance payment mode and exploring more efficient payment methods On November 18, the State Council issued the notice of the leading group of the State Council on deepening the reform of the medical and health system on further promoting the experience of deepening the reform of the medical and health system in Fujian Province and Sanming City It is suggested that Fujian medical electronic settlement center has realized the direct payment and settlement of medical insurance fund to pharmaceutical enterprises Comprehensive medical reform pilot provinces should take the lead in promoting medical insurance agencies to directly settle payments with drug production or circulation enterprises, and other provinces should also actively explore Brief comment: there is no doubt that the state does not know about the current problems of the hospital's payment collection It has not dealt with them before, but is actively seeking for better solutions Now, the direct payment of medical insurance is aimed at promoting the reform in a wider range It can be expected that once the local trial is successful, the next step will be to spread out nationwide, and the drug price may fall again The tide of price On November 17, the official website of the State Administration of market supervision publicly solicited opinions on the Interim Measures for reporting and rewarding major violations in the field of market supervision (Revised Draft for comments) (hereinafter referred to as the draft for comments) In the draft, the report and reward for major illegal acts are specified, and the current reward standard is improved In the draft, the scope of reporting and reward is expanded, not limited to the illegal activities such as manufacturing and selling fake and shoddy products, and 4 categories of major illegal behaviors and the illegal behaviors suspected of crimes transferred to judicial organs for filing are added, At the same time, the reward level is divided into three levels From the first level to the third level, 5%, 3% and 1% of the amount of fines and confiscations will be awarded respectively The rewards for cases without fines and confiscations will not be less than 2000, 1000 and 500, while the maximum rewards for major cases will not be more than 2 million yuan Brief comment: at a glance, the government's visit is to speed up the reform of market supervision system, effectively improve the efficiency of supervision and law enforcement and consumer rights protection, ensure the seriousness of the implementation of laws and regulations, use the full name to supervise enterprises, and fundamentally put an end to all illegal behaviors in the pharmaceutical industry Major pharmaceutical enterprises should be careful! 200W may make many people feel excited On November 21, Shanghai issued the work tips on "open price negotiation for drugs limited to drugstores" and other related matters In particular, the platform is required to push the full price negotiation information (the first batch) (701 product specifications) of drugs limited to drugstores to the inquiry and price negotiation system From November 25, all drugstores and relevant enterprises at the medical insurance fixed point are invited to do a good job in price negotiation confirmation All drugstores (medical insurance designated drugstores) are in the medical insurance fixed point Over the counter) the retail price of drugs sold shall be determined by the designated drugstore of medical insurance and the drug manufacturer Shanghai drugstore price negotiation officially came into effect today, which means that the designated medical institutions in Shanghai will realize price synchronization, prescription synchronization and differential synchronization with medical insurance drugstores The introduction of this plan basically means the end of the era of high price of related drugs in Shanghai retail pharmacies This time, we officially opened the inquiry of drugs from drugstores, which shows that the intention of reducing the price of drugstores is very firm For enterprises, it will be sooner or later for retail pharmacies to settle the payment of medical insurance according to the price selected in 4 + 7 The original intention of the state joint mining and expansion is to explore the price formation mechanism and generate a unified medical insurance payment price Brief comment: Generally speaking, the high price of drugstores is well known If the price of drugs in hospitals is only to reduce the price of drugs, the drugstore is also a key place for reform The author once asked a friend who is a drug terminal market, and said frankly that the current price reduction policies have no great impact on him, and how much or how much to sell On November 19, Shandong Provincial Food and Drug Administration and Chongqing Municipal Food and drug administration respectively issued the notice of drug quality sampling, in which Shandong Province announced 64 batches of unqualified drugs and Chongqing Municipality announced 4 batches of unqualified drugs Of the 64 batches of substandard drugs in Shandong Province, 4 batches are preparations, including chloramphenicol eye drops, jiuweishenqi capsules, Huoshen capsules, Hesha qudian pills; 60 batches are pieces of Chinese herbal medicines, including alum, fried cassia seed, cortex of the earth, pinellia, etc Four batches of drugs produced by four enterprises in Chongqing are not in conformity with the regulations They are Shenyang Shenlong Pharmaceutical Co., Ltd., Harbin Sanmu Pharmaceutical Co., Ltd., Guangxi Shengkang Pharmaceutical Co., Ltd of hengtuo group, Huanglian Shangqing pill, Qianlie huangguantong tablet, Qiangli Zhikening capsule, laobeikechuan capsule and Huanglian Shangqing pill For the above unqualified drugs, the two bureaus have ordered the departments to take necessary control measures such as sealing up, seizure, suspension of sales, recall, etc., and investigate and deal with them in accordance with relevant laws and regulations This week, the disclosure of the third quarter performance report of Listed Companies in 2019 is coming to an end According to incomplete statistics, there are 101 enterprises with R & D expenses of more than 50 million yuan among A-share and Hong Kong share listed pharmaceutical enterprises, including 56 pharmaceutical enterprises with R & D expenses of more than 100 million yuan in the first three quarters, and three pharmaceutical enterprises of Baiji Shenzhou, Hengrui and Fosun have a total of nearly 10 billion yuan The R & D investment of 8 patent pharmaceutical enterprises has increased year-on-year, with 14 pharmaceutical enterprises having R & D investment Development investment accounts for more than 10% of operating revenue In the first three quarters of 2019, the R & D expenses of 101 pharmaceutical companies totaled about 28.214 billion yuan, including 56 pharmaceutical companies with R & D expenses exceeding 100 million yuan, Baiji Shenzhou, Hengrui pharmaceutical and Fosun Pharmaceutical companies with R & D expenses exceeding 1 billion yuan, with a total R & D expenses of about 9.7 billion yuan, accounting for more than 10% of revenue Brief comment: it's common sense that drug R & D is difficult and expensive, but it's still impressive under the R & D data in the first three quarters of 2019 However, from the overall data, there are still so many enterprises that are not stingy in their investment Perhaps, it also proves the prospect of innovative drugs Last week, Amgen officially implemented the measure of cutting nearly 150 employees in the neuroscience business on the east coast of the United States On November 19, Amgen said it would cut another 172 employees in its headquarters and other business areas Effective December 31, this year, it involves employees in the R & D, operation and business sectors Although this time it also affected the personnel in the headquarters of Thousand Oaks, California, most of the layoffs were still targeted at the "grassroots" employees in the United States Before that, Amgen cut down the neuroscience R & D department and all employees of the plan, not only because of repeated failures in R & D, but also because of large investment and heavy losses The layoff may be due to the competition of new bio generic drugs It is precisely because of the fierce competition that Amgen's overall sales fell by 2% and 3% respectively in the second and third quarter of this year compared with the same period last year Recently, Shijiazhuang Yiling Pharmaceutical Co., Ltd issued a notice, and the company deliberated and passed the proposal on the investment and construction of modern Chinese medicine industrialization projects by wholly-owned subsidiaries, investing 5.034 billion yuan in the construction of modern Chinese medicine industrialization projects The announcement shows that in order to further improve the company's comprehensive competitive strength and future sustainable development momentum, we will make full capacity reserves for the development of traditional Chinese medicine formula granules, traditional Chinese medicine tablets, health products and other businesses According to Yiling pharmaceutical, the construction of the project is based on the strategic consideration of the company's future development and is in line with the company's development strategy of growing and strengthening its main business It is not only conducive to further improving the strategic layout of the company's production base of traditional Chinese medicine and health industry, but also to expanding the production capacity of traditional Chinese medicine tablets, decoction pieces and health products It can also be used for the company's future development of traditional Chinese medicine formula particles and extract business Good production capacity reserve, so as to achieve the purpose of optimizing the company's product structure, is of great significance to enhance the company's core competitiveness We believe that everyone is still concerned about the existence of traditional Chinese medicine formula granules in the market As one of the few sub sectors in the pharmaceutical industry that maintain ultra-high growth, the annual compound growth rate of the market has reached 30% in recent years The prospect cannot be underestimated Yiling pharmaceutical has invested 5 billion yuan in such a large amount to lay out traditional Chinese medicine formula granules, or it has taken a fancy to this huge market At present, 409 kinds of formula granules have been approved by Hebei Provincial Food and Drug Administration for clinical research of formula granules, and the continuously developed formula granules have been put into the market, which may become the biggest competitor of Shenwei pharmaceutical industry in the future On November 19, Yan'an Bikang decided to shut down Jiujiu technology 7-ADCA product line and Jiangsu Jianding Biotechnology Co., Ltd (hereinafter referred to as "Jianding technology") to ensure the sustainable operation and healthy development of Jiujiu technology 7-amino-3-deacetoxycephalosporanic acid (7-ADCA) is a semisynthetic intermediate of cephalosporin antibiotics However, the market of cephalosporin pharmaceutical intermediates has been in a downturn recently, and the "anti restriction" policy issued by the state has further intensified the contraction of product market demand, and the capacity utilization and profitability of 7-ADCA products have declined.